PT - JOURNAL ARTICLE AU - MASAYUKI HAYASHI AU - HIROYUKI TSUCHIYA AU - NORIO YAMAMOTO AU - MICHIAKI KARITA AU - TOSHIHARU SHIRAI AU - HIDEJI NISHIDA AU - AKIHIKO TAKEUCHI AU - KATSURO TOMITA TI - Caffeine-potentiated Chemotherapy for Metastatic Carcinoma and Lymphoma of Bone and Soft Tissue DP - 2005 May 01 TA - Anticancer Research PG - 2399--2405 VI - 25 IP - 3C 4099 - http://ar.iiarjournals.org/content/25/3C/2399.short 4100 - http://ar.iiarjournals.org/content/25/3C/2399.full SO - Anticancer Res2005 May 01; 25 AB - Background: We previously reported that caffeine-potentiated chemotherapy induced significantly good response in patients with musculoskeletal sarcomas. In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy. Patients and Methods: Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy. Results: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer. Good responses (gross tumor shrinkage >30%, or histologically >90% necrosis) to chemotherapy were seen in all five patients. Survival time was >1 year in all patients, and three out of five patients presented no evidence of local recurrence or metastasis at the final follow-up. Conclusion: Caffeine-potentiated chemotherapy may be of benefit for malignant tumors other than musculoskeletal sarcoma.